REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...

Nevro Corp. NVRO reported a loss per share of 70 cents in the first quarter of 2024 compared with the year-ago quarter’s loss of 98 cents. The metric beat the Zacks Consensus Estimate by 31.37%.

Nevro is a company that has developed a spinal cord stimulation implant to treat chronic pain. See why I will remain on the sidelines on NVRO stock for now.

Nevro’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 37.18%. Image Source: Zacks Investment Research Let’s delve deeper.

By Nevro Corp. Nov 18, 2024 Nov 18, 2024Updated Nov 18, 2024 ...

Worldwide revenue for the fourth quarter of 2024 was $105.5 million, a decrease of 9.1% as reported and 9.2% on a constant currency basis, compared with $116.2 million in the fourth quarter of ...

Nevro Corp. (NVRO) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Angie McCabe - Vice President, Investor Relations & Corporate Communications Kevin Thornal - CEO and ...

Nevro's high-frequency neurostimulation cuts diabetic neuropathy pain by 80% in 2-year study By Andrea Park Aug 16, 2023 11:46am Nevro spinal cord stimulation neurostimulation diabetic neuropathy ...

Nevro. Corp. closed the acquisition of privately held Vyrsa Technologies Inc., adding the company’s V1 implant for sacroiliac (SI) joint fusion to its product line for chronic pain. Nevro paid $40 ...